Member Info for Nolupus

Why Sorry ? I hope your gut is right ...

But i only believe what i see :-)

RdR....Tim does'nt run anything....He is just a "figurine" or a mouthpiece if you like..imv

Tim is CHAIRMAN of both companies....but don't forget who has the real, power in IMM...not Dimitri and not Tim :-)

Time for action...NOT TALK...imv

Guys, it's great to have rose tinted glasses but reality is another....

At the moment, IMM are still burning dwindling cash on UREKA and Nucant as well as on the MAP and the extension trial....

Untill we get an update ....The situation is not as brillant as some will like us to think....imv

Twitter is the pump and dumpers best friend :-)

@dallo

Imm WISH to recruit up to a max 500 people for the MAP as they Wished to recruit 100 people for the extension trial but as you know, they could only find around 60...

Expectations are high when you listen to Tim....but i only listen to myself :-)

BOL

@dallo

Not many people would invest over 100 million to pay for another P3 trial with 1000 patients , imv....

Just trying to recruit 1000 patients would take years...

But everyone to their own opinion !

Dallo,

You are talking about a sub group within a sub group....a bit like a needle in a hay stack....

@dallo

The spike at the end of november was due to "pump and dumpers" imo and we are back to 11p , where we were before ....

Just waiting ....

Retour du Renard....Why not ring your friend Dimitri or get your pals to do more Tweets :-)

Today;you sound more like Trump pesting against the Fed than the fervent ramper of Tim and Imm of just a few weeks ago....

What a change...

Retour du renard....You have changed your tune ...hmm as well as your position in IMM we may assume...pff

What is TIm up to ??

Is the problem due to Incanthera's IPO ?

IMM , what a failure in 2018......

ImmuPharma has granted Incanthera a period of exclusivity until 31st December 2018, during which the Company and Incanthera will finalise the terms of a Definitive Licence Agreement for the Nucant technology. These terms are expected to include, but will not be limited to the following:
Incanthera will pay a licence payment to ImmuPharma of £1m, with this payment to be made via the issuance of new ordinary shares in Incanthera. This payment in shares is separate and will be in addition to the shareholding which Immupharma currently holds as described above;
Incanthera will be responsible for all of the development costs for the Nucant programme; and
All future commercialisation revenues will be shared equally between the two companies

Stockraiser.....Did the fire burn out the floor boards ??

The SP has moved up.....but a far cry from what some people were expecting...

To Eli Lilly in lupus....

http://www.cerclefinance.com/default.asp?pub=valactu&isin=US5324571083&art=537298

Halfbutt...When do you expect 30p ??

And WHY ?

Saxonaxe, the only other market not requesting FDA approval...is the BLACK market :-)

S

Nothing New...just Patience is requested